Sarcopedia

MalignantSoft tissue

Leiomyosarcoma

Synonyms: LMS, Smooth muscle sarcoma

Second most common STS

Quick Facts

Behaviour

Malignant

Category

Soft tissue

Grade

Variable

Synonyms

  • LMS
  • Smooth muscle sarcoma

Category

Soft tissue

Behaviour

Malignant

Grade

Variable

Gender

M = F

Tissue of Origin

Smooth muscle

Epidemiology

  • Second most common STS in adults
  • Peak incidence 50-70 years
  • Can arise in any location with smooth muscle
  • Often deep-seated and large at diagnosis

Clinical Features

  • Painless or mildly painful mass
  • Rapid growth in some cases
  • May present with complications (GI bleeding if visceral)

Location

  • Retroperitoneum
  • Deep tHigh
  • GI tract
  • Biliary tract
  • Subcutaneous tissues (rare)

Imaging

  • MRI shows heterogeneous T2 signal
  • Varying enhancement post-contrast
  • May show necrosis or hemorrhage
  • Difficult to distinguish from Benign leiomyoma

Pathology

  • Fascicular arrangement of smooth muscle cells
  • Increased mitotic activity
  • Spindle cell morphology
  • Cytologic atypia

Genetics

  • No specific recurrent cytogenetic abnormality
  • Complex karyotypes common

Treatment

  • Wide surgical excision primary treatment
  • Adjuvant chemotherapy for High-grade/large tumours
  • Radiotherapy for unresectable or recurrent disease

Prognosis

  • Grade and size most important prognostic factors
  • 5-year survival 50% for High-grade
  • Retroperitoneal location associated with worse prognosis

Key Points

  • Second most common STS
  • Often presents at advanced stage
  • Grade and depth crucial for treatment planning
  • Regular imaging Follow-up essential

Workup - Local Imaging

MRI with contrast

Workup - Biopsy

  • Core needle biopsy recommended
  • Assess grade and mitotic activity

Workup - Staging

CT CAP

Follow-up Summary

  • Years 1–2: 3–4 monthly clinical review + CXR; MRI primary site at 3 months post-op then 6-monthly
  • CT chest every 3–4 months for first 2 years (pulmonary metastasis is primary concern)
  • Years 3–5: 6-monthly clinical review + CXR; CT chest 6-monthly
  • Years 6–10: Annual clinical review + CXR; CT chest annually
  • Discharge at 10 years with documented self-monitoring advice
  • Radiotherapy patients: monitor irradiated field for late effects at each review